Optimizing ibrutinib bioavailability: Formulation and assessment of hydroxypropyl-β-cyclodextrin-based nanosponge delivery systems
Background: The current research aims to improve the oral bioavailability of ibrutinib (IBR), a class II drug with low solubility, through the formulation of nanosponges (NSPs) that incorporate IBR, utilizing Hydroxypropyl β-cyclodextrin (HPβCD) and 1,1′-carbonyldiimidazole (CDI) as cross-linking ag...
Saved in:
Main Authors: | Sunitha Sampathi, Nitiraj Kulkarni, D.V.R.N. Bhikshapathi, Jagadish V. Tawade, Nainaru Tarakaramu, Rzgar Farooq Rashid, Aziz Kubaev |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-01-01
|
Series: | Current Research in Pharmacology and Drug Discovery |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S259025712500001X |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Unlocking Dabrafenib’s Potential: A Quality by Design (QBD) Journey to Enhance Permeation and Oral Bioavailability through Nanosponge Formulation
by: Konda Sri Chaya Reddy, et al.
Published: (2025-01-01) -
Complexation of Z-ligustilide with hydroxypropyl-β-cyclodextrin to improve stability and oral bioavailability
by: Lu Yapeng, et al.
Published: (2014-06-01) -
A superior preparation method for daidzein-hydroxypropyl-β-cyclodextrin complexes with improved solubility and dissolution: Supercritical fluid process
by: Pan Hao, et al.
Published: (2017-03-01) -
Phase I study of pembrolizumab in combination with ibrutinib for the treatment of unresectable or metastatic melanoma
by: Yuan Yao, et al.
Published: (2025-02-01) -
5-Fluorouracil-β-Cyclodextrin conjugates:Linker strategies to enhance the anticancer efficacy and reduce the side effects
by: Liangliang Hu, et al.
Published: (2025-03-01)